| Biological activity | A2ti-1 is selective, high affinity annexin A2/S100A10 isotetramer (A2t) inhibitor, IC50 is 24 μM. A2ti-1 specifically disrupt the protein interaction between A2 and S100A10. A2ti-1 can prevent human papillomavirus type 16 (HPV16) infection. |
| target | IC50: 24 μM (A2t) |
| in vitro study | A2ti-1 (compound 1 B) is an annexin A2-S100A10 protein-protein interaction blocker. A2ti-1 (100 μ m; For 72 hours) reduces HPV16 PsV infection of HeLa cells in a dose-dependent manner. A2ti-1 (10, 25, 50, 75,100 μ m; 24 hours) significantly reduces CFDA-SE-labelled HPV16 PsV entry into HeLa cells in a dose-dependent manner. Cell Viability Assay Cell Line: HeLa cells Concentration: 100 μ M Incubation Time: For 72 hours Result: Reduced HPV16 PsV infection of HeLa cells in a dose-dependent manner with 100% inhibition of infection observed at 100 μ M and similar results were observed in HaT cells. |
|
Cell Line:
| HeLa cells |
|
Concentration:
| 100 μM |
|
Incubation Time:
| For 72 hours |
|
Result:
| Reduced HPV16 PsV infection of HeLa cells in a dose-dependent manner with 100% inhibition of infection observed at 100 μM and similar results were observed in HaCaT cells. |
